Ultragenyx (RARE) Pharmaceutical announced that the first patient has been dosed in the Aurora study evaluating the efficacy and safety of GTX-102, an investigational antisense oligonucleotide for Angelman syndrome. Data from the Aurora study will expand the population of Angelman patients treated to include both younger and older patients and those with other non-deletion AS genotypes not included in the Phase 3 Aspire study. The fully enrolled Phase 3 Aspire study of GTX-102 is focused on patients aged 4 to 17 years with a genetically confirmed diagnosis of full maternal UBE3A gene deletion.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RARE:
- Ultragenyx’s MPS VII Study: A Closer Look at Market Implications
- Ultragenyx’s Ongoing Study on UX111: A Potential Game-Changer for MPS IIIA Treatment
- Ultragenyx’s LC-FAOD Study: A Strategic Move in Rare Disease Management
- Ultragenyx’s GTX-102 Study: A Potential Game-Changer for Angelman Syndrome
- Ultragenyx’s DTX401 Study: A Decade-Long Commitment to Patient Safety